{"nctId":"NCT00118365","briefTitle":"Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps","startDateStruct":{"date":"1998-07"},"conditions":["Precancerous Condition"],"count":375,"armGroups":[{"label":"Arm II (placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo","Other: laboratory biomarker analysis"]},{"label":"Arm I (eflornithine and sulindac)","type":"EXPERIMENTAL","interventionNames":["Drug: eflornithine","Drug: sulindac","Other: laboratory biomarker analysis"]}],"interventions":[{"name":"placebo","otherNames":["PLCB"]},{"name":"eflornithine","otherNames":["2-difluoromethylornithine","DFMO","difluromethylornithine"]},{"name":"sulindac","otherNames":["Aflodac","Algocetil","Clinoril","SULIN"]},{"name":"laboratory biomarker analysis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Criteria:\n\n* History of \\>= 1 surgically resected adenomatous polyp of the colon measuring \\>= 3 mm within the past 5 years\n* Screening colonoscopy performed within the past 6 months\n* All polyps must have been removed during colonoscopy, pathologically examined, and archived\n* No prior surgical resection removing \\> 40 cm of the colon\n* No personal or family history of familial polyposis or hereditary non-polyposis colon cancer\n* SWOG 0-1\n* Bilirubin =\\< 2.0 mg/dL\n* AST and ALT =\\< 2 times normal\n* Creatinine =\\< 1.5 mg/dL\n* Urine protein =\\<, urine casts 0-3, urine WBC and RBC count 0-5 cells by urinalysis\n* No history of inflammatory bowel disease\n* No gastric or duodenal ulcers within the past 12 months\n* Gastric or duodenal ulcers that were adequately treated \\> 24 months ago are allowed\n* No symptomatic gastric or duodenal ulcers\n* Not pregnant or nursing\n* Negative pregnancy test\n* Must have regional geographic stability over the next 36 months\n* Pure tone audiometry evaluation normal\n* Patients with \\>= 20 dB of uncorrectable hearing loss (for age) of any 2 contiguous frequencies are not allowed\n* No invasive malignancy within the past 5 years except adequately treated nonmelanoma skin cancer, level I (or Breslow \\< 0.76 mm) cutaneous melanoma, Duke's A colon cancer, stage I cervical cancer, or stage 0 chronic lymphocytic leukemia\n* No severe metabolic disorder\n* No other significant acute or chronic disease that would preclude study participation\n* No history of abnormal wound healing or repair\n* No conditions that would confer risk of abnormal wound healing or repair\n* No history of allergy to NSAIDs or eflornithine\n* No concurrent chemotherapy\n* No concurrent corticosteroids on a regular or predictable intermittent basis\n* No concurrent radiotherapy\n* Concurrent calcium supplements (=\\< 1,000 mg/day) allowed\n* Concurrent lipid-lowering drugs (i.e., high-dose statins) allowed\n* No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) on a regular or predictable intermittent basis\n* Concurrent aspirin for cardiovascular prophylaxis (i.e., 81 mg/day) allowed\n* No concurrent anticoagulants on a regular or predictable intermittent basis\n* No concurrent treatment for gastric or duodenal ulcers","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Detection of Any Adenoma at the End of the Study","description":"Detection of any adenoma at the end of the study. This analysis is based on the participants who had the end-of-study colonscopy procedure done.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Any Adenoma at the End of the Study Stratified by Baseline Prostaglandin E2 (PGE2) and Treatment","description":"This analysis is based on the participants who had the end-of-study colonscopy procedure done and their baseline PGE2 values are available. The low PGE2 is defined as the values that are below the median PGE2 value in the analysis cohort. The high PGE2 is defined as the values that are above the median PGE2 value in the analysis cohort.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Any Adenoma at the End of the Study Stratified by Baseline Putrescine and Treatment","description":"The low is defined as the values that are below the median putrescine level in the analysis cohort. The high is defined as the values that are above the median putrescine level in the analysis cohort.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Any Adenoma at the End of the Study Stratified by Baseline Spermidine-to-spermine Ratio and Treatment","description":"The low is defined as the ratios that are below the median spermidine-to-spermine ratio in the analysis cohort. The high is defined as the ratios that are above the median spermidine-to-spermine ratio in the analysis cohort.\n\nIn the finalized datasaet, the total number of adnoma detected in the placebo group is 55. The descrepancy in the total number of adnoma detected in placebo group between Outcome Measure 1 and this oucome is due to the revolution of the datatset.\n\nThe analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"37","spread":null},{"groupId":"OG003","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Any Adenoma at the End of the Study Stratified by Prostaglandin E2 (PGE2) Response and Treatment","description":"PGE2 Responder = PGE2 values at 36-month are decreased by \\>=30% in PGE2 values from baseline PGE2 nonresponder = PGE2 values at 36-month are increased, or decreased by \\< 30% from baseline The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Any Adenoma at the End of the Study Stratified by Putrescine Response and Treatment","description":"Putrescine responder = Putrescine values at 36-month are decreased by \\>=30% from baseline Putrescine nonresponder = Putrescine values at 36-month are increased, or decreased by \\< 30% from baseline The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Detection of Any Adenoma at the End of the Study Stratified by Spermidine-to-spermine Ratio Response and Treatment","description":"Spermidine-to-spermine ratio responder = ratios at 36-month are decreased by \\>=30% from baseline Spermidine-to-spermine ratio nonresponder = ratios at 36-month are increased, or decreased by \\< 30% from baseline The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"44","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events With a Grade of 3 and Above","description":"Participants reported at least 1 adverse event with a grade of 3 and above, regardless if the event is defined as serious per protocol or other.\n\nPer protocol, not all grade 3 events are considered as serious events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline Putrescine by ODC Genotype","description":"ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":null},{"groupId":"OG001","value":"0.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline Spermidine by ODC Genotype","description":"ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null},{"groupId":"OG001","value":"2.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Baseline Spermine by ODC Genotype","description":"ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.82","spread":null},{"groupId":"OG001","value":"7.29","spread":null}]}]}]},{"type":"SECONDARY","title":"At the End of the Study - Putrescine Response by ODC Genotype","description":"Putrescine responder was defined as (tissue putrescine value at baseline - tissue putrescine value at the end of the study)/(tissue putrescine value at baseline) ≥ the threshold. Putrescine non-responder was defined as (tissue putrescine value at baseline - tissue putrescine value at the end of the study)/(tissue putrescine value at baseline) \\< the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.\n\nODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"31","spread":null},{"groupId":"OG003","value":"37","spread":null}]}]}]},{"type":"SECONDARY","title":"At the End of the Study - Spermidine Response by ODC Genotype","description":"Spermidine responder was defined as (tissue spermidine value at baseline - tissue spermidine value at the end of the study)/(tissue spermidine value at baseline) ≥ the threshold. Spermidine non-responder was defined as (tissue spermidine value at baseline - tissue spermidine value at the end of the study)/(tissue spermidine value at baseline) \\< the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.\n\nODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"At the End of the Study - Spermine Response by ODC Genotype","description":"Spermine responder was defined as (tissue spermine value at baseline - tissue spermine value at the end of the study)/(tissue spermine value at baseline) ≥ the threshold. Spermine non-responder was defined as (tissue spermine value at baseline - tissue spermine value at the end of the study)/(tissue spermine value at baseline) \\< the threshold. The thresholds range from 0.25 to 0.45 with an increment of 0.5. The below data are shown for the threshold of 0.30.\n\nODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"25","spread":null},{"groupId":"OG003","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Have Adenoma Recurrence in Each ODC1 Genotytpe by Treatment Group","description":"ODC genotype is the genotype of single nucleotide polymorphisms (SNP) in the ornithine decarboxylase (ODC) promoter The analysis cohort is based on the participants whose data are available and complete.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Biomarker in Adenoma: Apoptosis","description":"Apoptosis expression was assessed using cytoplasmic staining. The definitions for the category level for the Apoptosis are: 1. focal (less than 10% cells that are positively stained); 2. less than 50% cells are positively stained; 3. more than 50% cells are positively stained.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Biomarker in Adenoma - Ki-67","description":"Estimated mean percent of cells staining postivie for the Ki-67 based on the GEE approach with adjustment for covariates","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":null},{"groupId":"OG001","value":"63.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Biomarker in Adenoma: CEA","description":"carcino-embryonic antigen (CEA) is adenocarcinoma tissue marker that is expressed during adenoma formation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Biomarker in Adenoma: Sialyl-TN (B72.3)","description":"sialyl-Tn (B72.3) is adenocarcinoma tissue marker that is expressed during adenoma formation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Biomarker in Adenoma - p53","description":"Estimated mean percent of cells staining postivie for p53 based on GEE approach with adjument for covariates.\n\nTumor protein p53, also known as p53, cellular tumor antigen p53, phosphoprotein p53, or tumor suppressor p53, is a protein that in humans is encoded by the TP53 gene.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null},{"groupId":"OG001","value":"70.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Biomarker in Adenoma: Bcl-2","description":"bcl-2 is the anti-apoptotic protein BCL2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":191},"commonTop":["DIARRHEA","FATIGUE","HEADACHE","NAUSEA","COLD SYMPTOMS"]}}}